CliffBio
biologic

Polivy

polatuzumab vedotin-piiq

Loss of exclusivityJune 2031projected — 12-year biologic exclusivity estimate
CompanyGenentech →See this company's full patent-cliff portfolio

Drug detail

Brand namePolivy
Active ingredientpolatuzumab vedotin-piiq
Strength140MG
Dosage formFor Injection
RouteIntravenous
ModalityBiologic
FDA approvalJune 2019
Marketing statusRx

More from Genentech

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.